Jazz Pharmaceuticals (NASDAQ:JAZZ) Raised to Buy at UBS Group

UBS Group upgraded shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) from a neutral rating to a buy rating in a report published on Friday morning, MarketBeat reports. UBS Group currently has $179.00 price target on the specialty pharmaceutical company’s stock, up from their prior price target of $145.00.

A number of other equities analysts have also recently weighed in on the stock. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. JPMorgan Chase & Co. boosted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Barclays reaffirmed an “overweight” rating and issued a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $176.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Buy” and an average price target of $189.40.

Jazz Pharmaceuticals Trading Up 1.7 %

Shares of NASDAQ JAZZ opened at $138.81 on Friday. The company’s fifty day moving average is $128.14 and its 200-day moving average is $120.07. The stock has a market cap of $8.43 billion, a price-to-earnings ratio of 19.55, a P/E/G ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals has a twelve month low of $99.06 and a twelve month high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Insider Transactions at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 3,800 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the transaction, the executive vice president now directly owns 33,318 shares in the company, valued at $4,826,778.66. The trade was a 10.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the transaction, the chief executive officer now owns 439,744 shares in the company, valued at $53,785,088.64. This represents a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 25,193 shares of company stock worth $3,533,122 in the last ninety days. Insiders own 4.20% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. CWA Asset Management Group LLC bought a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter worth about $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Jazz Pharmaceuticals by 135.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after buying an additional 100,112 shares during the period. Centre Asset Management LLC bought a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth about $9,335,000. Moloney Securities Asset Management LLC bought a new stake in Jazz Pharmaceuticals in the 4th quarter valued at about $464,000. Finally, Pacer Advisors Inc. boosted its holdings in Jazz Pharmaceuticals by 15.3% in the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after purchasing an additional 278,465 shares during the period. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.